News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
NxStage Medical, Inc. Cuts Expected IPO Price Range
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Oct 26 (Reuters) - Medical device company NxStage Medical Inc. cut the expected price for its initial public offering to between $11 and $12 a share from a previous range of $13 to $15, according to a regulatory filing on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Earnings
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks
April 30, 2026
·
5 min read
·
Gabrielle Masson
IPO tracker
Avalyn beats expectations with $300M debut
April 30, 2026
·
11 min read
·
Editorial Team
Earnings
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
April 29, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Chiesi snaps up KalVista for $1.9B, betting big on rare disease med Ekterly
April 29, 2026
·
2 min read
·
Gabrielle Masson